drugset
drugset / Trial / NCT06039384

A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

NCT06039384 ↗

Phase 1 Terminated 6 enrolled Incyte Corporation Mirati Therapeutics Inc. · collab
RandomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of INCB099280 in combination with adagrasib and to establish the MTD or identify RDE(s) for the combination of INCB099280 and adagrasib.

Timeline

Start
2023-12-28
Primary completion
2025-04-11
Completion
2025-07-11

Outcome

Outcome not reported

Stopped (Business): “This was a strategic business decision. There were no safety concerns contributing to this decision.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Adagrasib Small molecule — —
Subject INCB099280 Unknown — —

Indications

cancer